Medically reviewed by the Sarv Health Team · Our editorial process

Who Should Not Take Psilocybin

Psilocybin isn't for everyone, and for some people it's genuinely dangerous. Bipolar disorder, a personal or family history of psychosis, lithium, and MAOIs are the hard exclusions. Uncontrolled blood pressure, pregnancy, and being under 18 rule it out too. Careful screening is most of what makes supervised psilocybin reasonably safe.

Most coverage of psychedelic therapy is about who it might help. This is the other half of the picture, and it's the half that keeps people out of emergency rooms.

Who is excluded from psilocybin therapy?

Research programs have spent decades working out who shouldn't be given a psychedelic, and the modern screening standard comes largely from a 2008 safety framework published by the Johns Hopkins group. The exclusions it sets out are still the backbone of trial design today. Ruled out entirely:

• Bipolar I or bipolar II disorder. The most consistently applied psychiatric exclusion, for reasons the next section gets into.
• Schizophrenia or any other psychotic disorder, current or past.
• A first or second-degree relative with schizophrenia or another psychotic disorder. Yes, a relative. Family history alone is disqualifying.
• Lithium. This one is a medication interaction rather than a diagnosis, and it's the most dangerous on the list.
• MAOIs.
• Pregnancy, or not using effective contraception.
• Resting blood pressure above 140/90, averaged across four readings on at least two separate days.

Trials also commonly screen out current substance dependence, and depending on the study, obsessive-compulsive disorder, panic disorder, dissociative disorders, and eating disorders. Notice how much of that list is unknowable without a proper assessment. You cannot screen yourself for a second-degree relative's psychiatric history by feel.

Why is bipolar disorder the biggest concern?

Because psilocybin can push someone into mania, and we have real-world numbers on how often. A 2023 survey published in the Journal of Psychopharmacology asked 541 people with bipolar disorder about their experiences using psilocybin outside of clinical settings. Just under a third, 32.2%, reported a negative or unwanted outcome during the trip or in the two weeks after. New or worsening manic symptoms were the single most common problem, affecting 14.2%. And 3.3% needed emergency care, meaning an emergency department visit or a psychiatric or medical hospitalization.

Put that last figure in perspective. Roughly one in thirty people ended up needing acute care. Many of the same respondents still described psilocybin as more helpful than harmful overall, and the authors argue the risk picture is more nuanced than a flat prohibition suggests. They also recommend careful symptom monitoring and further study, which is a very different thing from recommending you try it. If you have bipolar disorder, this is the article's clearest answer. Not now, and not without a psychiatrist involved in a research setting.

What if psychosis runs in your family?

The concern is triggering a first psychotic episode in someone already predisposed, and predisposition is partly inherited. Second-degree relatives of a person with schizophrenia carry roughly a six-fold increased chance of developing it themselves, which is why family history knocks someone out of a trial even when they've never had a symptom.

The reassuring part is how rare lasting psychosis is once screening is done properly. Across 1,200 experimental research participants in the older literature, exactly one had a psychotic reaction lasting longer than 48 hours. That's a rate of 0.8 per 1,000. And the person it happened to was the identical twin of someone with schizophrenia, meaning today's criteria would have excluded him before he ever got a dose.

That number is an argument for screening, not an argument for safety in general. It describes what happens to carefully filtered volunteers in supervised research, which is nearly the opposite of the conditions most recreational use happens under.

Which medications don't mix with psilocybin?

• Lithium is the one that can hurt you. Combining classic psychedelics with lithium has been associated with seizures and delirium. It appears on exclusion lists as an absolute barrier, not a caution. If you take lithium, the answer is no.
• MAOIs slow the breakdown of psilocin and can amplify its effects to a dangerous degree, with risk of dangerously high blood pressure and overheating. Any supervised use requires a long washout period first, managed by a prescriber.
• SSRIs and SNRIs aren't considered dangerous here, but they blunt the effect. These drugs desensitize the same 5-HT2A receptors psilocybin acts on, so the experience is often muted or absent. Serotonin syndrome remains a theoretical worry rather than a demonstrated one. What matters far more: never stop an antidepressant on your own to make a psychedelic work better. Discontinuation carries its own serious risks, and doing it unsupervised is how people get hurt while trying to be careful.
• Antipsychotics occupy 5-HT2A receptors and block psilocybin's effects, which is why clinicians reach for them to bring a difficult experience to an end.
• Tricyclic antidepressants and stimulants both add to psilocybin's cardiovascular load, and autonomic instability is the concern with either.

Two things people don't expect on this list: St. John's wort (Hypericum perforatum) and 5-HTP. Both are serotonergic, both are sold over the counter, and both appear on research exclusion lists alongside prescription drugs. "Herbal" and "available at the pharmacy without a prescription" tell you nothing about whether something interacts.

Does psilocybin strain the heart?

Psilocybin transiently raises heart rate and blood pressure. In a healthy screened adult that's unremarkable. If you have significant cardiovascular disease, unstable angina, a recent heart attack, or blood pressure that isn't controlled, it stops being unremarkable, which is why trials set that 140/90 ceiling and require a 12-lead ECG before anyone is dosed.

There's a separate cardiac question that almost nobody covers, and it's worth knowing because it cuts against the usual assumption that smaller doses are safer.

Psilocin binds the 5-HT2B receptor, and sustained overstimulation of 5-HT2B makes cardiac fibroblasts proliferate, which thickens heart valves and can stop them working properly. That's the mechanism behind valve disease caused by fenfluramine and several older ergot drugs. A 2024 analysis in the Journal of Psychopharmacology found psilocin's affinity for 5-HT2B sits below the threshold associated with fibrosis-inducing drugs, and concluded the risk applies specifically to chronic microdosing, taken a few times a week for months, rather than to occasional full doses spaced widely apart. The authors called for scheduled breaks and echocardiogram screening for long-term microdosers.

So the daily-small-dose routine that reads as the cautious option may be the one with the cardiac question mark attached.

What about pregnancy, breastfeeding, and being young?

Pregnant people are excluded from every trial, as is anyone not using effective contraception. There's no safety data for psilocybin in pregnancy or breastfeeding, and no ethical way to generate it quickly. Absence of data is not reassurance.

For adolescents, the honest position is that the trials were done in adults and the results don't transfer. Psilocybin acts on a serotonin system that's still developing through the teens, the regulated state programs in Oregon and Colorado are adults-only, and it remains federally illegal regardless.

Can psilocybin cause lasting perceptual changes?

Rarely, yes. Hallucinogen persisting perception disorder, or HPPD, involves visual disturbances that continue after the drug has cleared: trails, halos, static, drifting patterns. A 2022 scoping review describes it as uncommon but serious, and notes the research still hasn't pinned down who's most at risk.

Uncommon is not the same as impossible, and it's a real reason not to treat repeat psychedelic use as consequence-free.

What does proper screening actually look like?

If you're evaluating a program or a facilitator, this is the checklist worth holding them to. Research-grade screening includes a structured psychiatric interview covering your own history and your family's, a medical history and physical exam, a 12-lead ECG, blood chemistry and hematology panels, urinalysis, a full medication and supplement review, and repeated blood pressure readings on separate days.

A provider who doesn't ask about your family's psychiatric history, or who waves off your medication list, is not screening you. They're selling you something.

Get emergency help immediately for: chest pain, a seizure, psychotic symptoms that don't fade as the drug wears off, or thoughts of harming yourself. If you're having thoughts of suicide right now, that's a reason to contact a crisis line or emergency services today, not a reason to seek out a psychedelic.

A whole-person note

If you've landed here because conventional treatment hasn't worked and psilocybin looked like the door out, that frustration is real and worth taking seriously. It's also worth knowing that "psilocybin isn't for me" doesn't mean nothing is. Treatment-resistant depression has other options with far more safety data behind them, and the mundane levers still matter more than most people expect: sleep, daylight, movement, iron and thyroid status, alcohol.

Gentler plant medicines have a genuine place for everyday stress, low mood, and restless sleep, and they're much better studied for those uses than psilocybin is.

This article is for general wellness and educational purposes only and is not medical advice. Consult a qualified healthcare provider before using herbs — especially if you are pregnant, nursing, or taking medication.

Our editorial process